Here, we first summarize the PI3K pathway alterations associated with the pathogenesis of breast cancer and the lessons about PI3K pathway inhibitors learned from clinical trails, with rational combination strategies in breast cancer treatment. This evidence concerns the gene PIK3CD and breast carcinoma.